Scarica l'app Stockscreener
1.80
1.12%
0.02
Pre-mercato:
1.71
-0.09
-5.00%
Precedente Chiudi:
$1.78
Aprire:
$1.74
Volume 24 ore:
3.21M
Relative Volume:
1.15
Capitalizzazione di mercato:
$128.18M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-2.40
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
+20.81%
1M Prestazione:
+29.50%
6M Prestazione:
+561.28%
1 anno Prestazione:
+57.89%
Intervallo 1D:
$1.67
$1.8199
Intervallo di 1 settimana:
$1.44
$1.8199
Portata 52W:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.80 | 126.76M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.56 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.90 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
211.41 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Will Ovid Therapeutics Inc. stock deliver long term returnsWeekly Trade Review & Verified Short-Term Plans - Newser
Will Ovid Therapeutics Inc. stock gain from strong economy2025 Top Gainers & Fast Moving Stock Trade Plans - Newser
Is Ovid Therapeutics Inc. (1OT) stock dividend growth reliableMarket Trend Review & Free Real-Time Volume Trigger Notifications - Newser
How Ovid Therapeutics Inc. (1OT) stock correlates with oil markets - Newser
IPO Launch: Is Ovid Therapeutics Inc stock positioned well for digital economyWeekly Gains Summary & Weekly Stock Performance Updates - BỘ NỘI VỤ
November 2025's Top Penny Stock Opportunities - simplywall.st
What analysts say about Ovid Therapeutics Inc 1OT stockVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
Ovid Therapeutics (OVID): HC Wainwright Raises Price Target to $2.00 | OVID Stock News - GuruFocus
HC Wainwright & Co. Maintains Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms - Citeline News & Insights
Is Ovid Therapeutics Inc. stock overvalued by current metricsJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com
Visual trend scoring systems applied to Ovid Therapeutics Inc.Earnings Risk Summary & Detailed Earnings Play Alerts - newser.com
Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
What consensus target says about Ovid Therapeutics Inc. (1OT) stock2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Is Ovid Therapeutics Inc. stock cheap at current valuation2025 Market Outlook & Expert Curated Trade Setups - newser.com
Regression analysis insights on Ovid Therapeutics Inc. performanceDollar Strength & High Yield Equity Trading Tips - newser.com
Ovid Therapeutics Reports Q3 2025 Financial Results - MSN
Combining machine learning predictions for Ovid Therapeutics Inc. - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.2025 Short Interest & Community Trade Idea Sharing - newser.com
Historical volatility pattern of Ovid Therapeutics Inc. visualizedWeekly Investment Summary & Free High Accuracy Swing Entry Alerts - newser.com
Leerink Partners Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
OVID: Leerink Partners Initiates Coverage with 'Outperform' Rati - GuruFocus
Leerink Partners Initiates Ovid Therapeutics at Outperform With $5 Price Target - MarketScreener
Can trapped investors hope for a rebound in Ovid Therapeutics Inc.2025 Market Sentiment & Daily Stock Trend Reports - newser.com
Ovid Therapeutics (OVID) Receives Positive Outlook from Analyst - GuruFocus
Published on: 2025-11-16 07:02:40 - newser.com
Price to book ratio of Ovid Therapeutics Inc. – HAM:1OT - TradingView
Published on: 2025-11-14 21:11:45 - newser.com
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.30%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):